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Introduction: Cases of esophageal metastasis of breast cancer are extremely rare. We present the case of a patient
who developed recurrence as esophageal metastasis following treatment of bilateral breast cancer. Early-stage
gastric cancer was also found coincidentally.
Case presentation: An 86-year-old Japanese female patient with a history of bilateral breast cancer was found to
have a gastric mass on a medical examination. At 72 years of age, she had undergone a total mastectomy with
level II axillary lymph node dissection (pT3N0M0 stage II). Left breast cancer was found at the age of 79. A total
mastectomy was performed with level II axillary lymph node dissection (pT1N0M0 stage I). At the time of her
current admission, our patient complained of dysphagia. A repeat gastrofiberscopy revealed a submucosal lesion in
her middle esophagus, located 27cm distal to her incisors, as well as a known type I tumor of the gastric cardia.
Computed tomography showed a mass lesion in her middle esophagus that had grown extraluminally and
infiltrated the tracheal bifurcation and her left primary bronchus. A boring biopsy of the esophageal lesion
was performed under ultrasonic monitoring, and a pathological diagnosis of poorly differentiated adenocarcinoma
of the esophagus was obtained. The biopsy of the cardiac lesion revealed moderately differentiated adenocarcinoma
of the stomach. The expression status of her hormone receptors indicated that the esophageal lesion reflected
metastatic recurrence of her breast cancer with coincidental primary gastric cancer (cT1N0M0 stage IA).
Conclusions: Esophageal metastasis of breast cancer is extremely rare. An individualized treatment plan
combining multimodal approaches should therefore be devised according to the patient’s status.Introduction
Distant metastasis from primary breast cancer often oc-
curs in the bones, lungs and liver. There are a few re-
ports of metastasis to the gastrointestinal trunk [1], but
cases of esophageal metastasis are extremely rare [2,3].
We present the case of a patient who developed recur-
rence as esophageal metastasis following treatment of bi-
lateral breast cancer. Early-stage gastric cancer was also
found coincidentally. To the best of our knowledge,
there have been no previous reports of such a case. We
present this case with a discussion of the diagnosis and
treatment strategies.* Correspondence: spqv9ke9@view.ocn.ne.jp
Department of Surgical Oncology, Osaka City University Graduate School of
Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan
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An 86-year-old Japanese female patient with a history of
bilateral breast cancer was found to have a gastric mass
on a medical examination. She was referred to our hos-
pital for a workup and treatment. She had previously
undergone surgery for right breast cancer at 72 years of
age and subsequently underwent total mastectomy with
level II axillary lymph node dissection. The pathological
examination at that time revealed invasive ductal carcin-
oma with positive lymphovascular invasion (pT3N0M0
stage II). The tumor was positive for both estrogen re-
ceptor (ER) and progesterone receptor (PR), and did not
overexpress human epidermal growth factor receptor 2
(HER2). A total of 50Gy of external beam irradiation
therapy was administered to her residual mammary
gland, followed by endocrine therapy with 20mg of dailyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Gastrofiberscopy and fine-needle aspiration cytology. (a) Gastrofiberscopy revealed a submucosal lesion of the middle esophagus.
(b) Fine-needle aspiration cytology and a boring biopsy of the esophageal lesion were obtained under ultrasonic monitoring.
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to have left breast cancer at the age of 79 years. A total
mastectomy was performed with level II axillary lymph
node dissection, and invasive ductal carcinoma with
positive lymphovascular invasion (pT1N0M0 Stage I)
was diagnosed. As before, the tumor was positive for ER
and PR with no HER2 overexpression. She received ex-
tended adjuvant endocrine therapy of 1mg per day of
anastrozole for five years.
On her current admission, our patient complained of
dysphagia. Repeat gastrofiberscopy revealed a submuco-
sal lesion in her middle esophagus located 27cm distal
to her incisors (Figure 1a), as well as the known type I
tumor (semipedunculated type) of her gastric cardia
(Figure 2). Biochemistry and blood testing did not reveal
any abnormal values. Her level of squamous cell carcin-
oma antigen was elevated (5.4ng/mL); however, the
values of the other markers (carcinoembryonic antigen,
carbohydrate antigen 15–3, National Cancer Center-ST
439, cytokeratin 19 fragment) were within the normal
ranges. Mediastinal computed tomography showed a
mass lesion in her middle esophagus that had grown
extraluminally and infiltrated the tracheal bifurcation
and her left primary bronchus (Figure 3). There was no
hepatic or pulmonary metastasis. Fine-needle aspirationFigure 2 Gastrofiberscopy revealed a type I tumor (semipedunculatedcytology and a boring biopsy of the esophageal lesion
were performed under ultrasonic monitoring (Figure 1b),
and a pathological diagnosis of poorly differentiated
adenocarcinoma of the esophagus was obtained with posi-
tive ER staining on immunohistochemistry (Figure 4a). A
biopsy of the cardiac lesion revealed moderately differenti-
ated adenocarcinoma of the stomach (Figure 4b). Neither
hormone receptors nor HER2 were expressed in the gas-
tric lesion. The expression status of the hormone re-
ceptors indicated that the esophageal lesion reflected
metastatic recurrence of her breast cancer with coinci-
dental primary gastric cancer (cT1N0M0 stage IA).
Although our patient’s dysphagia progressed, neither in-
tensive chemotherapy nor highly invasive surgical therapy
were considered to be indicated due to her general condi-
tion and age. The esophageal lesion was treated with 2Gy
per day of external beam irradiation therapy for 30 days
(for a total of 60Gy). It remarkably reduced in size after
radiotherapy (Figure 5a), allowing oral inoculation.
The cardiac tumor exhibited no remarkable changes
(Figure 5b). Endoscopic submucosal dissection was
considered for the gastric tumor. Unfortunately, endo-
scopic ultrasonography (EUS) demonstrated that the
tumor had invaded her submucosal layer and it was
judged to be inoperable due to the risk of bleeding andtype) of the gastric cardia (a, b).
Figure 3 Mediastinal computed tomography showed a mass lesion on the middle esophagus that had grown extraluminally and had
infiltrated the tracheal bifurcation and the left primary bronchus (a, b).
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endocrine therapy for her breast cancer was prioritized
because the esophageal lesion of the breast cancer was
much more advanced and critical for our patient’s sta-
tus than the gastric cancer. She received metronomic
medication with daily oral administration of tegafur-uracil
(400mg per kilogram body weight), cyclophosphamide
(100mg/day) and medroxyprogesterone acetate (800mg/
day) based on her age and therapeutic history, as well as
the biological subtype of the tumor and presence of the
non-treated gastric cancer. She has since maintained a
good performance status on outpatient treatment with
chemo-endocrine therapy, and no disease progression had
been noted to date, six months after the radiation therapy.
Discussion
Gastrointestinal metastasis of breast cancer is rare, with
an incidence of 4.3% to 14.4% [1]. Although gastric me-
tastasis of breast cancer is sometimes reported [1], me-
tastasis to the esophagus occurs extremely rarely.
According to Borst and Ingold, who observed a total of
2,246 patients with breast cancer over 18 years, the inci-
dence of esophageal metastasis was only 0.4% [4]. There
are very few case reports of such metastasis [5-19]
(Table 1); based on a search of PubMed, only 20 casesFigure 4 Histological findings of the biopsy. (a) Poorly differentiated adhave been reported. We found no reports describing a
case of gastric metastasis of breast cancer accompanied
by gastric cancer or occurring after treatment for bilat-
eral breast cancer.
Esophageal metastasis of breast cancer is usually de-
tected at an average of approximately seven years (range
3.5 to 24 years) after breast resection [20]. Symptoms in-
clude dysphagia, hoarseness and weight loss; however,
such symptoms are observed only in approximately 30%
of patients [21]. Esophageal metastasis of breast cancer
causes compression or stenosis of the esophagus due to
metastasis within the esophageal wall or to the medias-
tinal lymph nodes near the esophagus. Therefore, the
mucosal surface is usually not involved. These features
were also found in our patient. Esophagography and en-
doscopy are the diagnostic tools. The findings of these
tests are characterized by regular stenosis of the esopha-
gus as well as a lack of abnormalities of the mucosal sur-
face. Biopsies often do not reveal malignant findings.
Therefore, submucosal boring biopsies and aspiration
cytology are recommended for biopsy-based diagnosis.
Our patient was given a diagnosis based on successful
EUS-guided fine-needle aspiration cytology and a boring
biopsy, an alternative method for obtaining submucosal
tumor tissues. Most esophageal metastases originatingenocarcinoma of the esophagus. (b) Adenocarcinoma of the stomach.
Figure 5 Gastrofiberscopy after radiotherapy. (a) The esophageal tumor was remarkably reduced in size. (b) The cardiac tumor showed no
remarkable change.
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Therefore, patients presenting with dysphagia should
not be assumed to have benign stricture involvement
even if a mucosal biopsy does not demonstrate malig-
nancy. As a result, the indications for EUS are useful in
such situations, as observed in our case.Table 1 Reported cases of esophageal metastasis from breast
Author Year Age Location
Haim et al. [5] 1989 50 Mt
Issacs et al. [6] 1989 60 Mt, Lt
Shimada et al. [7] 1989 55 Lt
Herrera [8] 1992 78 EGJ
Labenz et al. [9] 1993 61 Mt
Hastier et al. [10] 1994 42 Lt




Mizobuchi et al. [12] 1997 56 Lt
Fujii et al. [13] 1997 68 Mt
Wu et al. [14] 1998 83 Mt




Erman et al. [15] 2002 55 Mt
Sunada et al. [16] 2005 68 Mt
Koike et al. [17] 2005 72 Mt
52 Lt
Anaya et al. [18] 2006 67 EGJ
Wada et al. [19] 2009 70 Mt
Present case 2011 86 Mt
AOD, alive of disease; CT, chemotherapy; D, dilatation; DOD, dead of disease; EGJ, e
Mt, middle thoracic esophagus; OP, operation; RT, radiation therapy; S, stenting.The prognosis of metastatic breast cancer to the esopha-
gus is poor, and it is reasonable to regard the disease as a
highly advanced breast cancer [2,20]. Therefore, the thera-
peutic strategy should always be individually planned. Ac-
cording to a literature review, surgical therapy has been
performed in nine patients, four of whom survived forcancer
Latent interval (years) Treatment Survival
12 D/HT/RT 1 year/AOD
5 D/HT −/−
9 HT/OP 5 years/AOD
21 HT/OP Postop/DOD





22 D/HT/RT 4 years/DOD
7 CT/HT/OP 4 years/DOD
15 HT/OP 1 year/AOD
13 D/HT −/−
9 D 1 year/DOD
4 CT/D 0.1 years/DOD
3.5 D 1.5 years/AOD
11 D/S 0.4 years/DOD
11 CT/HT/RT 3 years/AOD
24 D/HT 0.7 years/AOD
23 OP 1 year/AOD
10 D/HT/S −/−
19 HT/OP 0.5 years/AOD
16 HT/RT 2.5 years/AOD
7 HT/RT 0.5 years/AOD
sophagogastric junction; HT, hormonal therapy; Lt, lower thoracic esophagus;
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the use of surgical treatment when deemed possible. By
contrast, three patients died postoperatively, suggesting
the highly invasive nature of surgical therapy when
adapted to esophageal lesions [22]. The remaining patients
were treated with dilatation, stenting and/or radiation in
13, three and six cases, respectively [5-19]. Only short-
term follow-up results are available for patients who
underwent dilatation and stenting (9). Radiation was ad-
ministered in six cases [5,11,15,19], with a relatively good
prognosis of more than one year reported for every pa-
tient. All five patients who survived for more than two
years received hormone therapy in combination with local
treatment with either surgery or radiation. These results
indicate that patients exhibiting a response to hormonal
therapy, as in our case, may be expected to demon-
strate a more favorable prognosis than patients with
hormone receptor-negatives tumors. According to our
review, as many as 13 of 24 patients with metastatic
breast cancer to the esophagus showed positive results
for ER and/or PR [5-8,11,17-19]. Therefore, it is thought
that active treatment should be provided based on the in-
trinsic subtype. It is important to administer appropriate
multimodal therapy with topical treatment for esophageal
lesions (for example, radiotherapy, esophageal bougienage
and esophagectomy) [7,20] and systemic treatment for
distant metastasis (for example, chemotherapy and
endocrine therapy).
The administration of individualized treatment accord-
ing to the intrinsic subtype is recommended in patients
with breast cancer. Endocrine therapy was selected in
our case because our patient’s breast cancer was classi-
fied as luminal A type (ER-positive, HER2-negative, Ki67
<14%). Toremifene, an aromatase inhibitor, was chosen
for endocrine therapy because tamoxifen had been used
for five years for the right breast cancer that developed
at 72 years of age, and anastrozole for the same duration
for the left breast cancer, possibly the lesion respon-
sible for the present metastasis, that developed at 79
years of age. The primary tumors of both her breasts
and the metastatic lesion demonstrated the same bio-
logical nature (ER-positive and HER2-negative). How-
ever, untreated early gastric cancer was also coincidentally
found in our patient. Therefore, combination therapy
was administered with tegafur-uracil, cyclophospha-
mide and medroxyprogesterone acetate. This combin-
ation therapy is reported to be useful for elderly
patients [23].
Conclusions
Esophageal metastasis of breast cancer is extremely rare.
An individualized treatment plan combining multimodal
approaches should therefore be devised according to the
patient’s status.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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